Edwards Lifesciences Corporation $EW Shares Bought by MAI Capital Management

Key Points

• MAI Capital Management increased its stake in Edwards Lifesciences Corporation by 32.7% during the first quarter, owning 85,927 shares valued at approximately $6.2 million.
• Several institutional investors also raised their positions in the company, with Jennison Associates LLC owning over 10 million shares after increasing its position by 34.3%.
• Edwards Lifesciences reported a quarterly earnings per share of $0.67, exceeding expectations, and projected earnings guidance for FY 2025 between $2.400 and $2.500.

MAI Capital Management grew its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 32.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,927 shares of the medical research company's stock after purchasing an additional 21,192 shares during the period. MAI Capital Management's holdings in Edwards Lifesciences were worth $6,228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in EW. Arlington Trust Co LLC boosted its position in Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after buying an additional 135 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after purchasing an additional 142 shares during the period. Versant Capital Management Inc grew its stake in Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after purchasing an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. Finally, Kera Capital Partners Inc. increased its holdings in Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock worth $224,000 after purchasing an additional 148 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.07 during midday trading on Friday, hitting $80.89. 2,283,330 shares of the company were exchanged, compared to its average volume of 3,528,339. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The firm has a market capitalization of $47.49 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 3.90 and a beta of 1.07. The business has a fifty day simple moving average of $78.77 and a two-hundred day simple moving average of $75.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock valued at $1,698,844 in the last ninety days. 0.34% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on EW shares. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a research report on Tuesday, July 29th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Finally, William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.